The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pilot SCAT trial: Spanish customized adjuvant chemotherapy (CT) based on BRCA1 mRNA expression levels (l) in resected stage II-IIIA non-small cell lung cancer (NSCLC) patients (p).
Jose Miguel Sanchez
No relevant relationships to disclose
Manuel Cobo
No relevant relationships to disclose
Rafael Arrabal
No relevant relationships to disclose
Bartomeu Massuti
No relevant relationships to disclose
Jose Manuel Rodriguez Paniagua
No relevant relationships to disclose
Teresa Moran
No relevant relationships to disclose
Julio Astudillo
No relevant relationships to disclose
Ulpiano Jimenez
No relevant relationships to disclose
Yat Wa Pun
No relevant relationships to disclose
David Aguiar Bujanda
No relevant relationships to disclose
Jorge Freixenet
No relevant relationships to disclose
Jose-Luis Gonzalez-Larriba
No relevant relationships to disclose
Florentino Hernando-Trancho
No relevant relationships to disclose
Jose Gómez-Codina
No relevant relationships to disclose
Juan-Carlos Penalver
No relevant relationships to disclose
Natividad Martinez Banaclocha
No relevant relationships to disclose
Guillermo Lopez-Vivanco
No relevant relationships to disclose
Joaquin Pac
No relevant relationships to disclose
Miquel Taron
No relevant relationships to disclose
Rafael Rosell
No relevant relationships to disclose